Johnson & Johnson (NYSE:JNJ) announced Wednesday that the European Commission has granted approval for its Darzalex subcutaneous formulation to be used as a monotherapy for adults diagnosed with high-risk smouldering multiple myeloma.

Johnson & Johnson (NYSE:JNJ) is one of the stocks that Jim Cramer shed light on. Cramer was incredibly bullish on the company as he said: “Now, sometimes in this game, you do just get lucky. You’ll come across a surprise quarter that tells you everything you need to know about what can cause a big

Johnson says he wants to put social workers at stops and launch an anti-smoking campaign. A council member who’s pushed for enforcement against smoking says the mayor’s ideas could lack teeth.

Johnson & Johnson's stock offers value with promising MedTech growth, raised guidance, strong dividends, and bullish technical momentum. Learn more on JNJ stock here.

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.

Johnson & Johnson is partnering with Pacira BioSciences for osteoarthritis of the knee, according to a July 22 news release. The agreement adds Zilretta, an injectable osteoarthritis treatment, to Johnson & Johnson’s portfolio.

It wasn't perfect for Johnson, who struggled in one of his five summer league games to total just five points on 2-of-10 shooting from the field and 0-of-5 shooting from three-point range in the Heat's loss to the Cleveland Cavaliers on July 13 in Las Vegas. He also shot under 30% from behind the arc during his five summer league appearances.

Johnson & Johnson ( ($JNJ) ) has released its Q2 earnings. Here is a breakdown of the information Johnson & Johnson presented to its investors.